Feasibility of post-authorization randomized controlled trials for conditionally authorized anticancer medicines-A multistakeholder perspective

Christine C. van Hattem; Amos de Jong; Jolien S. de Groot; Lourens T. Bloem

Feasibility of post-authorization randomized controlled trials for conditionally authorized anticancer medicines-A multistakeholder perspective

Christine C. van Hattem, Amos de Jong, Jolien S. de Groot, Lourens T. Bloem

Research output: Contribution to journal › Meeting Abstract › Other research output

Original language	English
Pages (from-to)	623-623
Number of pages	1
Journal	Pharmacoepidemiology and Drug Safety
Volume	32
Publication status	Published - Oct 2023

Cite this

@article{0d3b734131f7411cb8ba9b850da06a88,

title = "Feasibility of post-authorization randomized controlled trials for conditionally authorized anticancer medicines-A multistakeholder perspective",

author = "{van Hattem}, {Christine C.} and {de Jong}, Amos and {de Groot}, {Jolien S.} and Bloem, {Lourens T.}",

year = "2023",

month = oct,

language = "English",

volume = "32",

pages = "623--623",

journal = "Pharmacoepidemiology and Drug Safety",

issn = "1053-8569",

publisher = "John Wiley and Sons Ltd",

}

Feasibility of post-authorization randomized controlled trials for conditionally authorized anticancer medicines-A multistakeholder perspective. / van Hattem, Christine C.; de Jong, Amos; de Groot, Jolien S. et al.
In: Pharmacoepidemiology and Drug Safety, Vol. 32, 10.2023, p. 623-623.

Research output: Contribution to journal › Meeting Abstract › Other research output

TY - JOUR

T1 - Feasibility of post-authorization randomized controlled trials for conditionally authorized anticancer medicines-A multistakeholder perspective

AU - van Hattem, Christine C.

AU - de Jong, Amos

AU - de Groot, Jolien S.

AU - Bloem, Lourens T.

PY - 2023/10

Y1 - 2023/10

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=d7dz6a2i7wiom976oc9ff2iqvdhv8k5x&SrcAuth=WosAPI&KeyUT=WOS:001091511702465&DestLinkType=FullRecord&DestApp=WOS

M3 - Meeting Abstract

SN - 1053-8569

VL - 32

SP - 623

EP - 623

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

ER -